{"disease":{"id":"parkinsonism","name":"Parkinsonism","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":16,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"hyoscyamine","indication_name":"Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(-)-Atropine","generic_name":"Hyoscyamine","company_name":"University of Kansas Medical Center","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"hyoscyamine","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"trihexyphenidyl-hydrochloride","indication_name":"Parkinsonism Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Artane","generic_name":"TRIHEXYPHENIDYL HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"trihexyphenidyl","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"benztropine-mesylate","indication_name":"Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BENZTROPINE MESYLATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":33,"revenue":null,"mechanism":null},{"drug_id":"levodopa","indication_name":"Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inbrija","generic_name":"LEVODOPA","company_name":"Merz","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase Fyn","drug_class":"Aromatic Amino Acid [EPC]","quality_score":10,"revenue":null,"mechanism":"Levodopa works by crossing the blood-brain barrier and being converted into dopamine, a neurotransmitter that helps regulate movement and coordination."},{"drug_id":"levodopa","indication_name":"Postencephalitic parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inbrija","generic_name":"LEVODOPA","company_name":"Merz","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase Fyn","drug_class":"Aromatic Amino Acid [EPC]","quality_score":10,"revenue":null,"mechanism":"Levodopa works by crossing the blood-brain barrier and being converted into dopamine, a neurotransmitter that helps regulate movement and coordination."},{"drug_id":"pergolid","indication_name":"Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"pergolid","company_name":"University Hospital Muenster","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, Alpha-synuclein, D(1B) dopamine receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"metixene","indication_name":"Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Metixen","generic_name":"metixene","company_name":"Novartis","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2C","drug_class":"metixene","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"carbidopa","indication_name":"Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sinemet Cr","generic_name":"CARBIDOPA","company_name":"Aton","drug_phase":"marketed","molecular_target":"Lysine-specific demethylase 4E","drug_class":"Aromatic Amino Acid [EPC]","quality_score":54,"revenue":null,"mechanism":"Levodopa crosses the blood-brain barrier and is converted to dopamine in the brain, relieving Parkinson's disease symptoms."},{"drug_id":"carbidopa","indication_name":"Postencephalitic parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sinemet Cr","generic_name":"CARBIDOPA","company_name":"Aton","drug_phase":"marketed","molecular_target":"Lysine-specific demethylase 4E","drug_class":"Aromatic Amino Acid [EPC]","quality_score":54,"revenue":null,"mechanism":"Levodopa crosses the blood-brain barrier and is converted to dopamine in the brain, relieving Parkinson's disease symptoms."},{"drug_id":"bromocriptine","indication_name":"Postencephalitic parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Parlodel","generic_name":"BROMOCRIPTINE","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"D(2) dopamine receptor","drug_class":"Ergot Derivative","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"orphenadrine","indication_name":"Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norflex","generic_name":"ORPHENADRINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Muscle Relaxant","quality_score":48,"revenue":null,"mechanism":""},{"drug_id":"trihexyphenidyl-hydrochloride","indication_name":"Arteriosclerotic Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Artane","generic_name":"TRIHEXYPHENIDYL HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"trihexyphenidyl","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"trihexyphenidyl-hydrochloride","indication_name":"Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Artane","generic_name":"TRIHEXYPHENIDYL HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"trihexyphenidyl","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"trihexyphenidyl-hydrochloride","indication_name":"Postencephalitic parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Artane","generic_name":"TRIHEXYPHENIDYL HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"trihexyphenidyl","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"dexetimide","indication_name":"Neuroleptic-induced Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexbenzetimide","generic_name":"DEXETIMIDE","company_name":"","drug_phase":"phase_2","molecular_target":"Muscarinic acetylcholine receptor M2","drug_class":"dexetimide","quality_score":null,"revenue":null,"mechanism":"Dexbenzetimide works by blocking the M2 muscarinic acetylcholine receptor, which helps to regulate muscle contractions and other bodily functions."},{"drug_id":"lodosyn","indication_name":"Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lodosyn","company_name":"University of Miami","drug_phase":"discontinued","molecular_target":"Lysine-specific demethylase 4E, Aromatic-L-amino-acid decarboxylase, Tyrosine-protein kinase Fyn","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"lodosyn","indication_name":"Postencephalitic parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lodosyn","company_name":"University of Miami","drug_phase":"discontinued","molecular_target":"Lysine-specific demethylase 4E, Aromatic-L-amino-acid decarboxylase, Tyrosine-protein kinase Fyn","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"cogentin","indication_name":"Arteriosclerotic Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cogentin","company_name":"University of Southern California","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"cogentin","indication_name":"Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cogentin","company_name":"University of Southern California","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"cogentin","indication_name":"Postencephalitic parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cogentin","company_name":"University of Southern California","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"piribedil","indication_name":"Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trivastal","generic_name":"PIRIBEDIL","company_name":"","drug_phase":"phase_3","molecular_target":"Alpha-2C adrenergic receptor","drug_class":"piribedil","quality_score":null,"revenue":null,"mechanism":"Trivastal works by blocking the alpha-2C adrenergic receptor, which helps to increase dopamine levels in the brain."},{"drug_id":"trihexyphenidyl","indication_name":"Arteriosclerotic Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Artane","generic_name":"TRIHEXYPHENIDYL","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"trihexyphenidyl","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"trihexyphenidyl","indication_name":"Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Artane","generic_name":"TRIHEXYPHENIDYL","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"trihexyphenidyl","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"trihexyphenidyl","indication_name":"Postencephalitic parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Artane","generic_name":"TRIHEXYPHENIDYL","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"trihexyphenidyl","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"procyclidine","indication_name":"Arteriosclerotic Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kemadrine","generic_name":"PROCYCLIDINE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"procyclidine","indication_name":"Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kemadrine","generic_name":"PROCYCLIDINE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"procyclidine","indication_name":"Postencephalitic parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kemadrine","generic_name":"PROCYCLIDINE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"biperiden","indication_name":"Arteriosclerotic Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Akineton","generic_name":"BIPERIDEN","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Anticholinergic","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"biperiden","indication_name":"Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Akineton","generic_name":"BIPERIDEN","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Anticholinergic","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"biperiden","indication_name":"Postencephalitic parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Akineton","generic_name":"BIPERIDEN","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Anticholinergic","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"amantadine","indication_name":"Arteriosclerotic Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gocovri","generic_name":"AMANTADINE","company_name":"Endo","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"Influenza A M2 Protein Inhibitor","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"amantadine","indication_name":"Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gocovri","generic_name":"AMANTADINE","company_name":"Endo","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"Influenza A M2 Protein Inhibitor","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"amantadine","indication_name":"Postencephalitic parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gocovri","generic_name":"AMANTADINE","company_name":"Endo","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"Influenza A M2 Protein Inhibitor","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"benzatropine","indication_name":"Arteriosclerotic Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cogentin","generic_name":"benzatropine","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Anticholinergic","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"benzatropine","indication_name":"Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cogentin","generic_name":"benzatropine","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Anticholinergic","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"benzatropine","indication_name":"Postencephalitic parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cogentin","generic_name":"benzatropine","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Anticholinergic","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gocovri","indication_name":"Arteriosclerotic Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"GOCOVRI","company_name":"Oregon Health and Science University","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"Influenza A M2 Protein Inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"gocovri","indication_name":"Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"GOCOVRI","company_name":"Oregon Health and Science University","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"Influenza A M2 Protein Inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"gocovri","indication_name":"Postencephalitic parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"GOCOVRI","company_name":"Oregon Health and Science University","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"Influenza A M2 Protein Inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"amantadin","indication_name":"Arteriosclerotic Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amantadin","company_name":"Centre Hospitalier Universitaire de Nice","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Sigma non-opioid intracellular receptor 1, Glutamate [NMDA] receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"amantadin","indication_name":"Parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amantadin","company_name":"Centre Hospitalier Universitaire de Nice","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Sigma non-opioid intracellular receptor 1, Glutamate [NMDA] receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"amantadin","indication_name":"Postencephalitic parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amantadin","company_name":"Centre Hospitalier Universitaire de Nice","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Sigma non-opioid intracellular receptor 1, Glutamate [NMDA] receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"bromocriptin","indication_name":"Postencephalitic parkinsonism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bromocriptin","company_name":"University Hospital, Bonn","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, Alpha-synuclein, D(1B) dopamine receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":43,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04701177","title":"Digitally-enhanced, Decentralized, Multi-omics Observational Cohort","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100000,"lead_sponsor_name":"Greece 2021 Committee","has_results":false},{"nct_id":"NCT06203106","title":"NYSCF Scientific Discovery Biobank","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"New York Stem Cell Foundation Research Institute","has_results":false},{"nct_id":"NCT04214509","title":"LIPAD - LRRK2 International Parkinson's Disease Study","phase":"","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"University of Luebeck","has_results":false},{"nct_id":"NCT03924414","title":"Trial of Parkinson's And Zoledronic Acid","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2650,"lead_sponsor_name":"California Pacific Medical Center Research Institute","has_results":false},{"nct_id":"NCT06949865","title":"AI-Enhanced Optimization of Acute Levodopa Challenge Test","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT04846010","title":"Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"All Natural Medicine Clinic, LLC","has_results":false},{"nct_id":"NCT04057794","title":"PDGeneration: Mapping the Future of Parkinson's Disease","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1982,"lead_sponsor_name":"Parkinson's Foundation","has_results":false},{"nct_id":"NCT03076671","title":"More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease","phase":"NA","overall_status":"COMPLETED","enrollment_count":783,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT07386015","title":"Etiology-Phenotype-Outcome Pathway Study on Freezing of Gait (FOG)","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Tianjin Huanhu Hospital","has_results":false},{"nct_id":"NCT05222386","title":"Community Outreach for Palliative Engagement -- Parkinson Disease","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":632,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT06596746","title":"Neurodegenerative Diseases Progression Markers (MARKERS-NDD)","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Casa di Cura San Raffaele Cassino","has_results":false},{"nct_id":"NCT04858893","title":"Application of Machine Learning Method in Validation of Screening Cognitive Test for Parkinsonisms","phase":"","overall_status":"COMPLETED","enrollment_count":562,"lead_sponsor_name":"Ospedale Generale Di Zona Moriggia-Pelascini","has_results":false},{"nct_id":"NCT03368300","title":"Epidemiology and Pathophysiology of Parkinsonism in the Caribbeans","phase":"NA","overall_status":"UNKNOWN","enrollment_count":550,"lead_sponsor_name":"Centre Hospitalier Universitaire de la Guadeloupe","has_results":false},{"nct_id":"NCT03638479","title":"Utilizing Smart Devices to Identify New Phenotypical Characteristics in Movement Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":513,"lead_sponsor_name":"Universität Münster","has_results":false},{"nct_id":"NCT05308485","title":"Events Exposure as a Trigger of the Clinical Manifestations of Parkinson's Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia","has_results":false},{"nct_id":"NCT06420310","title":"Pesticides and Parkinson´s Disease","phase":"","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"Hospital Universitario de Burgos","has_results":false},{"nct_id":"NCT05127057","title":"Proactive and Integrated Management and Empowerment in Parkinson's Disease (PRIME-UK): A New Model of Care (PRIME-RCT)","phase":"NA","overall_status":"COMPLETED","enrollment_count":214,"lead_sponsor_name":"University of Bristol","has_results":false},{"nct_id":"NCT06501469","title":"Biomarkers in Parkinsonian Syndromes","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Non-profit organization for scientific research in Parkinson's disease and related disorders","has_results":false},{"nct_id":"NCT00368199","title":"Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes","phase":"","overall_status":"COMPLETED","enrollment_count":196,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT05954013","title":"Advance Care Planning and Care Coordination for People With Parkinson's Disease","phase":"NA","overall_status":"COMPLETED","enrollment_count":189,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT04797611","title":"STEM-Parkinson's Disease","phase":"NA","overall_status":"COMPLETED","enrollment_count":188,"lead_sponsor_name":"Scion NeuroStim","has_results":true},{"nct_id":"NCT04518059","title":"Misfolded Proteins in the Skin of People With Parkinson's Disease and Other Parkinsonism","phase":"","overall_status":"COMPLETED","enrollment_count":184,"lead_sponsor_name":"University Hospitals Cleveland Medical Center","has_results":false},{"nct_id":"NCT05902676","title":"The Effects Of Anticholinergic Burden On Daily Living Activities In Elderly Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":180,"lead_sponsor_name":"Izmir Ataturk Training and Research Hospital","has_results":false},{"nct_id":"NCT05320250","title":"Saliva and Extracellular Vesicles for Parkinson's Disease","phase":"","overall_status":"COMPLETED","enrollment_count":165,"lead_sponsor_name":"Fondazione Don Carlo Gnocchi Onlus","has_results":false},{"nct_id":"NCT03421899","title":"A Study Into the Underlying Biochemical Pathways Involved in Parkinson's Disease, Such as Mitochondrial (Cellular \"Powerhouse\") Dysfunction","phase":"","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT04799418","title":"STEM-PD Open Label Extension (OLE)","phase":"NA","overall_status":"TERMINATED","enrollment_count":148,"lead_sponsor_name":"Scion NeuroStim","has_results":true},{"nct_id":"NCT05638477","title":"Unstructured Eye Tracking as a Diagnostic and Prognostic Biomarker in Parkinsonian Disorders","phase":"NA","overall_status":"UNKNOWN","enrollment_count":122,"lead_sponsor_name":"Conor Fearon","has_results":false},{"nct_id":"NCT05273957","title":"A Model of Hospital-Territory Management Coordinated by a Case Manager to Improve the Care of Patients With Parkinsonism.","phase":"NA","overall_status":"UNKNOWN","enrollment_count":121,"lead_sponsor_name":"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","has_results":false},{"nct_id":"NCT04086160","title":"Effects of Transcranial Direct Current Stimulation (tDCS) on Motor Function in Schizophrenia Patients and Individuals at Risk for Psychotic Onset","phase":"NA","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Dr WANG Shumei","has_results":false},{"nct_id":"NCT07471230","title":"Evaluation of Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Biocells Medical","has_results":false},{"nct_id":"NCT06122662","title":"AMX0035 and Progressive Supranuclear Palsy","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":110,"lead_sponsor_name":"Amylyx Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT04308135","title":"Differences Between Patients With Vascular Parkinsonism and Parkinson's Disease","phase":"","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"Ain Shams University","has_results":false},{"nct_id":"NCT07257393","title":"Fall Risk Assessment in Parkinson's Disease Using Kinetikos Health","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Taipei Medical University Shuang Ho Hospital","has_results":false},{"nct_id":"NCT07207096","title":"Observational Case Series of Patients With Parkinson's Disease (PD) Attending a Complementary Medicine Neuro-degenerative Disease (NDD) Clinic.","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"St. Mary's University, Twickenham","has_results":false},{"nct_id":"NCT04928027","title":"Self-Reports of Executive Functions in Persons With Parkinson's Disease and Their Significant Others","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Old Dominion University","has_results":false},{"nct_id":"NCT03857607","title":"Natural History Study of ATP1A3-related Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Institute of Child Health","has_results":false},{"nct_id":"NCT05599659","title":"The Calgary Movement Disorders Advanced Care Pilot Program","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT04925622","title":"Complex Eye Movements in Parkinson's Disease and Related Movement Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Saccadous, Inc.","has_results":false},{"nct_id":"NCT07176091","title":"Clinical Efficacy of Intermittent Theta Burst Transcranial Magnetic Stimulation With Different Modes on Parkinson's Disease","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":90,"lead_sponsor_name":"Second Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT06032585","title":"TRANSPARK_LONG: The Diagnostic Value of Early Transcranial Ultrasound in Patients With Extrapyramidal Diseases in a Swedish Population","phase":"","overall_status":"COMPLETED","enrollment_count":74,"lead_sponsor_name":"Region Skane","has_results":false},{"nct_id":"NCT04075318","title":"Study of UB-312 in Healthy Participants and Parkinson's Disease Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"United Neuroscience Ltd.","has_results":true},{"nct_id":"NCT06174948","title":"The Use of the CUE1/CUE1+ in People With Parkinson's Disease and Related Disorders","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Queen Mary University of London","has_results":false},{"nct_id":"NCT05962489","title":"Sleep-specific DBS Therapy in Parkinson's Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":64,"lead_sponsor_name":"University of Minnesota","has_results":false},{"nct_id":"NCT04948684","title":"Efficacy of Botulinum Toxin for the Treatment of Dystonia Associated With Parkinson's Disease and Atypical Parkinsonism","phase":"","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"Hospital Avicenne","has_results":false},{"nct_id":"NCT04553835","title":"Effects of Rhythmic Auditory Stimulation on Movements in Individuals at Risk for Psychotic Onset and Schizophrenia Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Dr WANG Shumei","has_results":false},{"nct_id":"NCT07056348","title":"Long-term Brain Stimulation of the Motor Ventral Thalamus (VOP/VIM) to Improve Motor Function","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Jorge Gonzalez-Martinez","has_results":false},{"nct_id":"NCT06400017","title":"Mechanism and Application of DBS in the Treatment of PD","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT06350617","title":"Personalized rTMS Protocol Based on Functional Reserve to Enhance Ambulatory Function in PD Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT03477695","title":"Improving Posture in Parkinson's Patients Through Home-based Training and Biofeedback","phase":"NA","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Tel-Aviv Sourasky Medical Center","has_results":false},{"nct_id":"NCT07056361","title":"Stimulating Specific Brain Areas (VOP/VIM) With Electricity to Improve Movement and Muscle Control","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Jorge Gonzalez-Martinez","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}